Host: Neilanjan Nandi, MD 


Guest: Andres Yarur, MD 



  Irritable bowel disease (IBD) often requires a personalized approach to treatment. So what does the current therapeutic drug monitoring landscape look like? Dr. Neil Nandi speaks with Dr. Andres Yarur, Associate Professor of Medicine at Cedars-Sinai in Los Angeles, about therapeutic drug monitoring for IBD.

Exploring Therapeutic Drug Monitoring in IBD

Looking to digest the latest in gastroenterology? GI Insights is here to provide updates on screening guidelines, diagnostic options, and management tools for all diseases and disorders affecting the gastrointestinal tract.

Science & Medicine

Natural Sciences

Social Sciences

Medicine

Health

Alternative Health

Self-Help

Sexuality

Fitness & Nutrition

Host: Peter Buch, MD, FACG, AGAF, FACP 


  Guest: David P. Hudesman, MD 



  
    There’s been an increase in the elderly irritable bowel disease (IBD) population, and it’s estimated that a third of our overall IBD population will soon be over the age of 60. When managing and diagnosing these patients, there’s different factors to consider, like polypharmacy, biological versus chronological age, how fit these patients are versus how frail they are, and more. To take a deep dive into how IBD is affecting elderly patients, join Dr. Peter Buch as he speaks with Dr. David Hudesman, Professor of Medicine and Co-director of NYU Langone’s Inflammatory Bowel Disease Center. 

Elderly Patients with IBD: Management Strategies and Care

Host: Peter Buch, MD, FACG, AGAF, FACP 


  Guest: Francis Farraye, MD 



  
    Patients with inflammatory bowel disease (IBD) have an increased risk of developing infections, and some may be preventable with a vaccine. Approximately 70 percent of patients with ulcerative colitis or Crohn’s disease will be on immunosuppressive therapy at some point during their treatment course, so it’s best to try to address vaccines before they’re immunosuppressed. So to walk us through some strategies for increasing the number of patients with gastrointestinal diseases who get vaccinated, Dr. Peter Buch is joined by Dr. Farraye, Co-Author of the article, titled “How to Implement a Successful Vaccination Program in Outpatient Gastroenterology Practices: A Focus on Patients with Inflammatory Bowel Disease and Chronic Liver Disease,” which appeared in Gastroenterology in 2023 and Professor of Medicine at the Mayo Clinic in Jacksonville, Florida, where he also directs the Inflammatory Bowel Disease Center. 

Educating Gastrointestinal Patients About the Benefits of Vaccination

Host: Peter Buch, MD, FACG, AGAF, FACP 


  Guest: Alexander Ford, MD 



  
    Irritable bowel syndrome (IBS) is diagnosed using the ROME 4 criteria, and fortunately, most patients who meet the criteria for IBS clinically are unlikely to have another underlying explanation for their symptoms. However, a common misconception is that IBS is a diagnosis of exclusion, so to learn more about this and other controversies surrounding IBS, join Dr. Peter Buch as he speaks with Dr. Alexander Ford, Professor of Gastroenterology and Honorary Consultant of Gastroenterology at Leeds Institute of Medical Research at St. James University of Leeds. 

Overcoming Controversies of Irritable Bowel Syndrome

Host: Peter Buch, MD, FACG, AGAF, FACP 


  Guest: David Wan, MD 



  
    Many patients with lower gastrointestinal (GI) bleeding are on anticoagulants, and they may need specific reversal agents depending on what antithrombotic they’re on. Tune into this episode to learn more about the article that dives into the management and treatment of acute lower GI bleeding and the challenges along the way with Dr. Peter Buch as he speaks with Dr. David Wan, Associate Professor of Medicine at New York-Presbyterian/Weill Cornell Medical Center.

Managing and Treating Patients with Lower GI Bleeding

Host: Peter Buch, MD, FACG, AGAF, FACP 


  Guest: Katherine Falloon, MD 



  
    Extraintestinal manifestations (EIMs) that occur in inflammatory bowel disease (IBD) are almost any manifestation that occur outside the gastrointestinal tract. And patients with Crohn’s disease or ulcerative colitis are at an increased risk for developing these manifestations. So to review EIMs in IBD and discuss the importance of a multidisciplinary approach, Dr. Peter Buch is joined by Dr. Katherine Falloon, Gastroenterologist at the Cleveland Clinic.

Exploring Therapeutic Drug Monitoring in IBD

Download our free app to listen on your phone